Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Pcvx source : Www.sutrobio.com save search
Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
Published: 2023-01-09 (Crawled : 22:00) - sutrobio.com
PCVX | $60.25 -1.04% -1.05% 670K
|
Health Technology
|
| O: -0.3%
H: 1.79%
C: 0.35%
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
|
| O: 1.93%
H: 0.89%
C: -14.08%
stro-002 biopharma update cancer study ovarian cancer phase 1
Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer
Published: 2022-12-21 (Crawled : 13:00) - sutrobio.com
PCVX | $60.25 -1.04% -1.05% 670K
|
Health Technology
|
| O: 0.22%
H: 3.45%
C: 3.2%
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
|
| O: 4.79%
H: 1.43%
C: 0.0%
stro-002 biopharma update cancer ovarian cancer
Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract
Published: 2022-12-20 (Crawled : 22:00) - sutrobio.com
PPRUF | News | $340.0 37.56% 1.5K
|
Consumer Non-Durables
|
| O: 2.83%
H: 2.66%
C: -0.36%
PPRUY | News | $33.79 -0.11% 360K
|
Manufacturing
|
| O: 1.46%
H: 1.58%
C: 0.82%
PCVX | $60.25 -1.04% -1.05% 670K
|
Health Technology
|
| O: 0.22%
H: 3.45%
C: 3.2%
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
|
| O: 4.79%
H: 1.43%
C: 0.0%
biopharma grant agreement
Sutro Biopharma to Participate in Upcoming Investor Conferences
Published: 2022-11-23 (Crawled : 12:00) - sutrobio.com
PCVX | $60.25 -1.04% -1.05% 670K
|
Health Technology
|
| O: -0.29%
H: 1.41%
C: 0.32%
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
|
| O: 0.38%
H: 1.81%
C: -3.87%
biopharma
Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones
Published: 2022-11-08 (Crawled : 22:00) - sutrobio.com
PCVX | $60.25 -1.04% -1.05% 670K
|
Health Technology
|
| O: -1.05%
H: 2.21%
C: -2.28%
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
|
| O: 1.82%
H: 4.67%
C: 0.82%
biopharma financial
Sutro Biopharma to Participate in Upcoming Investor Conferences
Published: 2022-11-02 (Crawled : 11:00) - sutrobio.com
PCVX | $60.25 -1.04% -1.05% 670K
|
Health Technology
|
| O: -0.78%
H: 1.08%
C: -4.77%
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
|
| O: -0.26%
H: 1.3%
C: -5.18%
biopharma
Sutro Biopharma Announces Departure of Chief Medical Officer
Published: 2022-10-24 (Crawled : 11:00) - sutrobio.com
PCVX | $60.25 -1.04% -1.05% 670K
|
Health Technology
|
| O: 70.8%
H: 2.7%
C: -6.12%
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
|
| O: 0.71%
H: 14.96%
C: 13.91%
biopharma
Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference
Published: 2022-09-01 (Crawled : 11:00) - sutrobio.com
PCVX | $60.25 -1.04% -1.05% 670K
|
Health Technology
|
| O: -0.15%
H: 0.02%
C: -1.49%
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
|
| O: -0.35%
H: 4.26%
C: 4.08%
biopharma conference
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2022-08-19 (Crawled : 20:00) - sutrobio.com
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
| Email alert
Add to watchlist
PCVX | $60.25 -1.04% -1.05% 670K
|
Health Technology
| Email alert
Add to watchlist
biopharma nasdaq grants
Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones
Published: 2022-08-08 (Crawled : 21:00) - sutrobio.com
PCVX | $60.25 -1.04% -1.05% 670K
|
Health Technology
|
| O: -0.23%
H: 1.12%
C: 0.66%
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
|
| O: -0.48%
H: 14.98%
C: 7.14%
biopharma
Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference
Published: 2022-08-03 (Crawled : 11:00) - sutrobio.com
PCVX | $60.25 -1.04% -1.05% 670K
|
Health Technology
|
| O: 1.76%
H: 4.04%
C: 0.99%
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
|
| O: 2.18%
H: 6.22%
C: -4.62%
biopharma conference
Sutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck
Published: 2022-07-26 (Crawled : 20:00) - sutrobio.com
PCVX | $60.25 -1.04% -1.05% 670K
|
Health Technology
|
| O: 0.17%
H: 5.67%
C: 4.29%
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
|
| O: 0.96%
H: 4.45%
C: 1.59%
biopharma collaboration milestone
Sutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs
Published: 2022-07-12 (Crawled : 11:00) - sutrobio.com
PCVX | $60.25 -1.04% -1.05% 670K
|
Health Technology
|
| O: -0.43%
H: 3.17%
C: -0.52%
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
|
| O: 0.0%
H: 3.33%
C: 2.88%
biopharma research
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.